Streetbeat News

Price Targets

PCRX

Needham analyst Serge Belanger maintains a Buy rating on Pacira BioSciences (NASDAQ:PCRX) but lowers the price target from $43 to $22.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:14 am

GSBD

Wells Fargo analyst Finian O'Shea has upgraded Goldman Sachs BDC (NYSE:GSBD) from Underweight to Equal-Weight and lowered the price target from $14 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:14 am

PPC

BMO Capital has downgraded Pilgrims Pride (NASDAQ:PPC) from Outperform to Market Perform, while maintaining the price target at $46.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:13 am

TTD

Baird analyst Vikram Kesavabhotla maintains an Outperform rating on Trade Desk (NASDAQ:TTD) and raises the price target from $110 to $130.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:11 am

AKRO

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Akero Therapeutics (NASDAQ:AKRO) and maintained a $50 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:11 am

SMMT

HC Wainwright & Co. has initiated coverage on Summit Therapeutics (NASDAQ:SMMT) with a Buy rating and set a price target of $16.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:09 am

AKBA

HC Wainwright & Co. has maintained a Buy rating on Akebia Therapeutics (NASDAQ:AKBA) and raised the price target from $6 to $7.5.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:06 am

BHF

Wells Fargo analyst Elyse Greenspan has downgraded Brighthouse Financial (NASDAQ:BHF) from Equal-Weight to Underweight and set a price target of $40.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:03 am

BRO

Wells Fargo analyst Elyse Greenspan has upgraded Brown & Brown (NYSE:BRO) from Equal-Weight to Overweight and raised the price target from $94 to $112.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:00 am

ACXP

HC Wainwright & Co. analyst Ed Arce has reiterated a Buy rating on Acurx Pharmaceuticals (NASDAQ:ACXP) and maintained a $12 price target.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:00 am